Increased plasma conc w/ strong or moderate CYP3A inhibitors (eg, antifungals including ketoconazole, itraconazole, posaconazole, voriconazole; certain macrolides eg, erythromycin, clarithromycin & telithromycin; active substances to treat HIV/AIDS eg, cobicistat, indinavir, lopinavir, nelfinavir, ritonavir & saquinavir; as well as conivaptan & boceprevir) including grapefruit or grapefruit juice. Decreased plasma conc w/ strong or moderate CYP3A4 inducers [eg, dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarb, fosphenytoin, primidone, bosentan, efavirenz, etravirine, modafinil, dabrafenib, nafcillin or Hypericum perforatum
(St. John's wort)]. May have potential to increase or decrease plasma conc of CYP3A substrates. Has potential to alter conc of co-administered substrates of P-gp, BCRP, MATE1, MATE2-K, & BSEP.